Clopidogrel in a pediatric population: prescribing practice and outcomes from a single center.
BACKGROUND
This study aimed to provide descriptive information about off-label treatment practice with clopidogrel in a pediatric population.


METHODS
Patients less than 18 years of age prescribed clopidogrel between March 2002 and August 2005 were retrospectively identified at Children's Hospital, Boston. Data from the time of first documented clopidogrel use to the most recent follow-up assessment were collected. Adverse events were classified according to seriousness and relationship to clopidogrel.


RESULTS
Of the 90 patients in the study, 53% were boys. The median age of the patients was 6.7 years, and their median weight was 23.6 kg at first clopidogrel use. Prescriptions were predominantly for cardiac indications (96%), with a few for neurologic indications (4%). Common cardiac indications were history of thrombosis involving a conduit or shunt, abnormal vasculature with potential for low flow, and device placement. The median total dose was 1.3 mg/kg/day, and the duration of therapy varied from less than 1 day to 4 years (median, 45 days). Three patients experienced minor bleeding, all of whom were receiving concomitant acetylsalicylic acid. Another patient experienced catastrophic bleeding after vessel tear during catheterization. One patient with a fenestrated Fontan and poor ventricular function had baffle thrombosis and subsequent stroke while receiving clopidogrel and acetylsalicylic acid.


CONCLUSIONS
Clopidogrel was prescribed most often to prevent thrombosis in patients with cardiac disease. Patients with neurologic conditions also were treated. Bruising and bleeding events occurred rarely.
Maltz
Lily A
LA
Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA.
Gauvreau
Kimberlee
K
Connor
Jean A
JA
Jenkins
Kathy J
KJ
D000293:Adolescent; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D000077144:Clopidogrel; D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
Rev Med Liege. 2006 Sep;61(9):656-61
17112168
JAMA. 2005 Sep 14;294(10):1224-32
16143698
Pediatrics. 2004 Dec;114(6):1708-33
15574639
Lancet. 1996 Nov 16;348(9038):1329-39
8918275
Stroke. 2006 Apr;37(4):1120-2
16527995
J Pediatr. 2005 Nov;147(5):657-61
16291359
N Engl J Med. 2005 Mar 24;352(12):1179-89
15758000
Circulation. 2008 Jan 29;117(4):553-9
18195173
Lancet. 2004 Jul 24-30;364(9431):331-7
15276392
Lancet. 2005 Nov 5;366(9497):1607-21
16271642